Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has been assigned a $3.50 price target by analysts at Citigroup Inc. in a report issued on Thursday. The brokerage presently has a “hold” rating on the biotechnology company’s stock. Citigroup Inc.’s price target would indicate a potential upside of 23.67% from the company’s current price.

CATB has been the subject of several other reports. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price on shares of Catabasis Pharmaceuticals in a research report on Wednesday, June 21st. Oppenheimer Holdings, Inc. lowered their target price on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research report on Tuesday, August 15th. Finally, HC Wainwright raised their target price on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Catabasis Pharmaceuticals has a consensus rating of “Buy” and an average price target of $5.75.

Catabasis Pharmaceuticals (CATB) traded down 6.27% during midday trading on Thursday, reaching $2.84. The company had a trading volume of 7,531,284 shares. The company’s market capitalization is $63.85 million. Catabasis Pharmaceuticals has a 12-month low of $1.08 and a 12-month high of $5.51. The stock has a 50-day moving average price of $1.98 and a 200 day moving average price of $1.98.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. Equities analysts forecast that Catabasis Pharmaceuticals will post ($1.39) EPS for the current year.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/05/catabasis-pharmaceuticals-inc-catb-given-new-3-50-price-target-at-citigroup-inc.html.

Hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. bought a new position in shares of Catabasis Pharmaceuticals in the 1st quarter worth about $144,000. Renaissance Technologies LLC bought a new position in shares of Catabasis Pharmaceuticals in the 1st quarter worth about $106,000. Finally, Virtu KCG Holdings LLC bought a new position in shares of Catabasis Pharmaceuticals in the 2nd quarter worth about $271,000. 32.90% of the stock is owned by hedge funds and other institutional investors.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.